task_path stringlengths 3 199 ⌀ | dataset stringlengths 1 128 ⌀ | model_name stringlengths 1 223 ⌀ | paper_url stringlengths 21 601 ⌀ | metric_name stringlengths 1 50 ⌀ | metric_value stringlengths 1 9.22k ⌀ |
|---|---|---|---|---|---|
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | CLIP-C | https://arxiv.org/abs/2103.00020v1 | mAP | 42.58 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | CLIP-C | https://arxiv.org/abs/2103.00020v1 | mINP | 21.38 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | IVT | https://arxiv.org/abs/2208.08608v2 | Rank 1 | 43.65 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | IVT | https://arxiv.org/abs/2208.08608v2 | Rank 10 | 75.70 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | IVT | https://arxiv.org/abs/2208.08608v2 | Rank 5 | 66.50 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | IVT | https://arxiv.org/abs/2208.08608v2 | mAP | 37.22 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | IVT | https://arxiv.org/abs/2208.08608v2 | mINP | 20.47 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | SSAN | https://arxiv.org/abs/2107.12666v2 | Rank 1 | 35.10 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | SSAN | https://arxiv.org/abs/2107.12666v2 | Rank 10 | 71.45 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | SSAN | https://arxiv.org/abs/2107.12666v2 | Rank 5 | 60.00 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | SSAN | https://arxiv.org/abs/2107.12666v2 | mAP | 28.90 |
Text-based Person Retrieval with Noisy Correspondence | RSTPReid | SSAN | https://arxiv.org/abs/2107.12666v2 | mINP | 12.08 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | RDE | https://arxiv.org/abs/2308.09911v3 | Rank-1 | 74.46 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | RDE | https://arxiv.org/abs/2308.09911v3 | Rank-5 | 89.42 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | RDE | https://arxiv.org/abs/2308.09911v3 | Rank 10 | 93.63 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | RDE | https://arxiv.org/abs/2308.09911v3 | mAP | 66.13 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | RDE | https://arxiv.org/abs/2308.09911v3 | mINP | 49.66 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | DECL | https://dl.acm.org/doi/abs/10.1145/3503161.3547922 | Rank-1 | 70.29 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | DECL | https://dl.acm.org/doi/abs/10.1145/3503161.3547922 | Rank-5 | 87.04 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | DECL | https://dl.acm.org/doi/abs/10.1145/3503161.3547922 | Rank 10 | 91.93 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | DECL | https://dl.acm.org/doi/abs/10.1145/3503161.3547922 | mAP | 62.84 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | DECL | https://dl.acm.org/doi/abs/10.1145/3503161.3547922 | mINP | 46.54 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IRRA | https://arxiv.org/abs/2303.12501v1 | Rank-1 | 69.74 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IRRA | https://arxiv.org/abs/2303.12501v1 | Rank-5 | 87.09 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IRRA | https://arxiv.org/abs/2303.12501v1 | Rank 10 | 92.20 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IRRA | https://arxiv.org/abs/2303.12501v1 | mAP | 62.28 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IRRA | https://arxiv.org/abs/2303.12501v1 | mINP | 45.84 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | CLIP-C | https://arxiv.org/abs/2103.00020v1 | Rank-1 | 66.41 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | CLIP-C | https://arxiv.org/abs/2103.00020v1 | Rank-5 | 85.15 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | CLIP-C | https://arxiv.org/abs/2103.00020v1 | Rank 10 | 90.89 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | CLIP-C | https://arxiv.org/abs/2103.00020v1 | mAP | 59.36 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | CLIP-C | https://arxiv.org/abs/2103.00020v1 | mINP | 43.02 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IVT | https://arxiv.org/abs/2208.08608v2 | Rank-1 | 58.59 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IVT | https://arxiv.org/abs/2208.08608v2 | Rank-5 | 78.51 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IVT | https://arxiv.org/abs/2208.08608v2 | Rank 10 | 85.61 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IVT | https://arxiv.org/abs/2208.08608v2 | mAP | 57.19 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | IVT | https://arxiv.org/abs/2208.08608v2 | mINP | 45.78 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | SSAN | https://arxiv.org/abs/2107.12666v2 | Rank-1 | 46.52 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | SSAN | https://arxiv.org/abs/2107.12666v2 | Rank-5 | 68.36 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | SSAN | https://arxiv.org/abs/2107.12666v2 | Rank 10 | 77.42 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | SSAN | https://arxiv.org/abs/2107.12666v2 | mAP | 42.49 |
Text-based Person Retrieval with Noisy Correspondence | CUHK-PEDES | SSAN | https://arxiv.org/abs/2107.12666v2 | mINP | 28.13 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MapLight | https://arxiv.org/abs/2310.00174v1 | TDC.Caco2_Wang | 0.276 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Solubility_AqSolDB | 0.727 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Caco2_Wang | 0.288 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.HIA_Hou | 0.987 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Pgp_Broccatelli | 0.911 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Bioavailability_Ma | 0.7 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Lipophilicity_AstraZeneca | 0.533 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.BBB_Martins | 0.905 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.PPBR_AZ | 8.251 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.VDss_Lombardo | 0.612 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.CYP2D6_Inhibition_Veith | 0.794 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.CYP3A4_Inhibition_Veith | 0.721 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.CYP2C9_Inhibition_Veith | 0.877 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.CYP2D6_Substrate_CarbonMangels | 0.387 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.CYP3A4_Substrate_CarbonMangels | 0.648 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.CYP2C9_Substrate_CarbonMangels | 0.680 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Half_Life_Obach | 0.396 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Clearance_Microsome_AZ | 0.420 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.Clearance_Hepatocyte_AZ | 0.587 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.hERG | 0.806 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.AMES | 0.859 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.DILI | 0.933 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | XGBoost | https://arxiv.org/abs/2204.07532v3 | TDC.LD50_Zhu | 0.602 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | DeepMol | https://www.biorxiv.org/content/10.1101/2024.05.27.595849v1 | TDC.Caco2_Wang | 0.297 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Solubility_AqSolDB | 0.827 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Caco2_Wang | 0.393 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.HIA_Hou | 0.972 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Pgp_Broccatelli | 0.918 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Bioavailability_Ma | 0.672 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Lipophilicity_AstraZeneca | 0.574 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.BBB_Martins | 0.889 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.PPBR_AZ | 9.994 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.VDss_Lombardo | 0.561 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Inhibition_Veith | 0.616 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Inhibition_Veith | 0.829 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Inhibition_Veith | 0.742 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Substrate_CarbonMangels | 0.677 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Substrate_CarbonMangels | 0.639 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Substrate_CarbonMangels | 0.360 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Half_Life_Obach | 0.184 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Microsome_AZ | 0.586 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.Clearance_Hepatocyte_AZ | 0.382 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.hERG | 0.841 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.AMES | 0.823 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.DILI | 0.875 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | MLP-RDKit2D | https://arxiv.org/abs/2102.09548v2 | TDC.LD50_Zhu | 0.678 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Solubility_AqSolDB | 0.776 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Caco2_Wang | 0.401 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.HIA_Hou | 0.974 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Pgp_Broccatelli | 0.892 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Bioavailability_Ma | 0.632 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.Lipophilicity_AstraZeneca | 0.572 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.BBB_Martins | 0.855 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.PPBR_AZ | 9.373 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.VDss_Lombardo | 0.241 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2D6_Inhibition_Veith | 0.646 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.CYP3A4_Inhibition_Veith | 0.851 |
Therapeutics Data Commons > TDC ADMET Benchmarking Group | tdcommons | AttentiveFP | https://arxiv.org/abs/2102.09548v2 | TDC.CYP2C9_Inhibition_Veith | 0.749 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.